[MAYBANK] QoQ Annualized Quarter Result on 30-Sep-2022 [#3]

Announcement Date
23-Nov-2022
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2022
Quarter
30-Sep-2022 [#3]
Profit Trend
QoQ- 3.66%
YoY- 0.47%
View:
Show?
Annualized Quarter Result
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
Revenue 62,642,640 59,120,096 50,913,872 48,729,108 46,245,734 47,628,804 45,959,390 23.00%
PBT 12,851,292 12,223,396 12,153,266 11,794,854 11,276,484 11,889,300 10,886,595 11.72%
Tax -3,391,194 -2,893,012 -3,780,264 -3,574,766 -3,284,592 -3,542,948 -2,565,080 20.51%
NP 9,460,098 9,330,384 8,373,002 8,220,088 7,991,892 8,346,352 8,321,515 8.95%
-
NP to SH 9,207,920 9,061,620 8,234,949 8,090,189 7,804,280 8,179,572 8,096,229 8.98%
-
Tax Rate 26.39% 23.67% 31.10% 30.31% 29.13% 29.80% 23.56% -
Total Cost 53,182,542 49,789,712 42,540,870 40,509,020 38,253,842 39,282,452 37,637,875 26.00%
-
Net Worth 90,255,278 85,878,424 85,956,773 83,648,436 84,698,618 83,815,975 85,785,748 3.45%
Dividend
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
Div 6,991,393 - 6,991,393 4,436,973 6,703,207 - 6,887,464 1.00%
Div Payout % 75.93% - 84.90% 54.84% 85.89% - 85.07% -
Equity
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
Net Worth 90,255,278 85,878,424 85,956,773 83,648,436 84,698,618 83,815,975 85,785,748 3.45%
NOSH 12,054,127 12,054,127 12,054,127 11,976,250 11,970,013 11,878,513 11,878,513 0.98%
Ratio Analysis
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
NP Margin 15.10% 15.78% 16.45% 16.87% 17.28% 17.52% 18.11% -
ROE 10.20% 10.55% 9.58% 9.67% 9.21% 9.76% 9.44% -
Per Share
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
RPS 519.68 490.46 422.38 410.01 386.35 400.97 387.03 21.77%
EPS 76.38 75.16 68.80 67.75 65.44 68.88 69.66 6.34%
DPS 58.00 0.00 58.00 37.33 56.00 0.00 58.00 0.00%
NAPS 7.4875 7.1244 7.1309 7.0383 7.0759 7.0561 7.2241 2.42%
Adjusted Per Share Value based on latest NOSH - 11,976,250
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
RPS 519.13 489.93 421.93 403.82 383.24 394.70 380.87 23.00%
EPS 76.31 75.09 68.24 67.04 64.67 67.78 67.09 8.98%
DPS 57.94 0.00 57.94 36.77 55.55 0.00 57.08 1.00%
NAPS 7.4795 7.1168 7.1233 6.932 7.0191 6.9459 7.1091 3.45%
Price Multiplier on Financial Quarter End Date
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
Date 30/06/23 31/03/23 30/12/22 30/09/22 30/06/22 31/03/22 31/12/21 -
Price 8.63 8.57 8.70 8.58 8.59 8.94 8.30 -
P/RPS 1.66 1.75 2.06 2.09 2.22 2.23 2.14 -15.61%
P/EPS 11.30 11.40 12.73 12.60 13.18 12.98 12.17 -4.83%
EY 8.85 8.77 7.85 7.93 7.59 7.70 8.21 5.14%
DY 6.72 0.00 6.67 4.35 6.52 0.00 6.99 -2.59%
P/NAPS 1.15 1.20 1.22 1.22 1.21 1.27 1.15 0.00%
Price Multiplier on Announcement Date
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
Date 30/08/23 24/05/23 27/02/23 23/11/22 25/08/22 26/05/22 24/02/22 -
Price 9.11 8.57 8.75 8.55 8.84 8.98 8.64 -
P/RPS 1.75 1.75 2.07 2.09 2.29 2.24 2.23 -14.95%
P/EPS 11.93 11.40 12.81 12.56 13.56 13.04 12.67 -3.94%
EY 8.39 8.77 7.81 7.96 7.38 7.67 7.89 4.19%
DY 6.37 0.00 6.63 4.37 6.33 0.00 6.71 -3.41%
P/NAPS 1.22 1.20 1.23 1.21 1.25 1.27 1.20 1.11%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment